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membrane. Nuclear sparing would directly 
implicate the nuclear membrane in this 
phenomenon. Because of their fluorescence 
properties, which allow study by confocal 
microscopy and flow cytometry, 
anthracyclines have also been used 
extensively to investigate MDR. Thus sensitive 
(MGH-U1 and RT112) and MDR (MGH-U1R 
and MGH-U1-MMC) bladder cancer cell lines 
were used. Adherent cells from each cell line 
were individually microinjected with 
epirubicin (0.5 mg/mL) and a 77 kDa 
fluorescein isothiocyanate (FITC)-dextran 
(0.5 mg/mL). The pattern of nuclear epirubicin 
uptake in injected cells was then evaluated by 
confocal microscopy. The 77 kDa FITC-dextran 
allowed easier identification of injected cells 
and was also excluded from their nuclei.
 
RESULTS
 
Sensitive bladder cancer cell lines all showed a 
nuclear accumulation pattern of epirubicin, 
consistent with their normal uptake after 
exposure to epirubicin. The MDR cell lines 
showed the characteristic nuclear-sparing 
pattern of epirubicin uptake, similar to the 
normal uptake pattern after epirubicin 
exposure. The 77 kDa FITC-dextran showed 
clearly which cells had been microinjected, 
and was excluded from the nuclei of all 
injected cells. Cell viability was confirmed by 
acridine-orange staining after initial 
visualization of injected cells.
 
CONCLUSION
 
The nuclear membrane is responsible for the 
nuclear exclusion of epirubicin in MDR cells. 
Further work is necessary to determine the 
mechanisms involved.
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OBJECTIVE
 
To assess whether microinjecting epirubicin 
into cells showing multidrug resistance (MDR, 
common to many cancers, including bladder 
cancer, with resistance to, e.g. anthracyclines 
and mitomycin C) spares the nucleus, as when 
these drugs accumulate, distribution in MDR 
cells characteristically spares the nucleus, 
suggesting that the nuclear membrane is 
responsible for excluding cytotoxic drugs 
from MDR nuclei.
 
MATERIALS AND METHODS
 
Nuclear exclusion of drugs is an important 
feature of resistance in MDR cells, as many 
MDR-susceptible drugs have cytotoxic 
actions within the nucleus. Drug 
accumulation in ‘classical’ P-glycoprotein-
mediated MDR cells is greatly reduced by 
efflux. Microinjection of epirubicin into the 
cytoplasm of MDR cells bypasses the P-
glycoprotein efflux pump on the plasma 
 
INTRODUCTION
 
Multidrug resistance (MDR) in bladder cancer 
is common, with up to 75% of patients 
expressing markers of MDR at presentation 
[1,2]. Anthracyclines and mitomycin C belong 
to the MDR family of drugs and have been 
widely used as adjuvant intravesical 
chemotherapy for superficial bladder cancer 
[3–7]. After resection, adjuvant intravesical 
chemotherapy using these agents can reduce 
bladder cancer recurrence rates by 40–60% 
[4,7]. However, because of the development of 
MDR, many superficial bladder cancers will 
recur. MDR genes, including MDR1, MRP1, 
MRP2 and MRP3, have been shown to 
increase in cases of recurrent and residual 
cancer after chemotherapeutic treatment 
with doxorubicin [8,9].
Anthracyclines have been used extensively to 
investigate MDR because they autofluoresce, 
which allows their study by confocal 
microscopy and flow cytometry. Previous 
studies showed that anthracycline 
accumulation in ‘classical’ P-glycoprotein 
(P-gp)-mediated MDR cells is dramatically 
reduced by drug efflux [10–14]. Of the 
drug that accumulates, the distribution 
characteristically spares the nucleus [15–17], 
a phenomenon which has been shown in cell 
lines of different origins [16–18]. Primary cells 
cultured from bladder cancer explants also 
show heterogeneity in their nuclear uptake of 
epirubicin, with many having the MDR 
phenotype [19].
Anthracyclines have several nuclear cytotoxic 
actions, including intercalation-prompted, 
topoisomerase-II-dependent DNA cleavage, 
and DNA damage secondary to intracellular 
free-radical production. Mitomycin C 
is modified to its active metabolite 
intracellularly by a bioreductive alkylation 
reaction. The active moiety inhibits DNA 
synthesis, cross-links DNA, induces single-
strand DNA breaks by alkylation of the O-6 
guanine residue, and causes DNA damage 
secondary to superoxide and hydroxyl radical 
production. Thus, nuclear exclusion of these 
drugs will clearly reduce their effectiveness, 
contributing to resistance in MDR cells. The 
role of the nuclear membrane in this nuclear-
sparing phenomenon in MDR cancer cells has 
not been clearly established. Microinjection of 
cytotoxic drugs into MDR cells provides a 
novel means of studying MDR status and 
mechanisms of MDR. Microinjection of 
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epirubicin into the cytoplasm of MDR cells 
bypasses the plasma membrane P-gp efflux 
pump; if MDR cells microinjected with 
epirubicin still show their characteristic 
nuclear sparing, this would provide direct 
evidence of the role of the nuclear membrane 
and establish another mechanism of MDR in 
bladder cancer.
 
MATERIALS AND METHODS
 
Drug-sensitive bladder TCC cell lines used 
were MGH-U1 (Human female TCC cell 
line, donated by Prof John Masters, UCL) 
and RT112 (Human female TCC cell line, 
purchased from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen, Cat No. 
ACC 418, Germany). The MDR variants used 
were MGH-U1R (donated by Prof John 
Masters) and MGH-U1-MMC (MDR subline of 
MGH-U1, generated in-house). MGH-U1R 
was produced by prolonged low-dose 
exposure of MGH-U1 to doxorubicin [20] and 
MGH-U1-MMC by prolonged low-dose 
exposure of MGH-U1 to mitomycin C [21]. The 
inhibitory concentration required to reduce 
the viable biomass by half of that in controls 
for each of these cell lines, calculated from 
tetrazolium cytotoxicity assays for epirubicin 
and mitomycin C, respectively, were (
 
m
 
g/mL): 
RT112, 1 and (not assessed); MGH-U1, 2 and 
1; MGH-U1R, 
 
ª
 
80 and 
 
ª
 
80; and MGH-U1-
MMC, 
 
>
 
80 and 
 
>
 
80, respectively. The MDR cell 
lines had 
 
>
 
40 times the resistance to 
epirubicin and 
 
>
 
80 times the resistance to 
mitomycin C than their sensitive counterpart 
[21].
All cell lines were cultured in Dulbecco’s 
Modified Eagle’s Medium supplemented 
with 2 mmol/L 
 
L
 
-glutamine, 10% fetal calf 
serum and 100 
 
m
 
g/mL of both penicillin/
streptomycin solution (Sigma Chem Co., 
Poole, UK). Cells were passaged using trypsin-
EDTA (Sigma) when 85% confluent. Cultures 
were maintained in a humidified incubator 
with 5% CO
 
2
 
 at 37 
 
∞
 
C.
For experiments, cells were harvested using 
trypsin-EDTA (Sigma) and the cell density 
adjusted to 1 
 
¥
 
 10
 
4
 
 cells/mL. Cells were 
subcultured in 40 mm Petri dishes, grown 
to 50% confluence (48–72 h in total) and 
then used for microinjection or incubation 
experiments. Before microinjection the 
culture medium was changed to one 
containing 10 mmol/L HEPES (1 : 100 HEPES 
buffering solution, Cat no. 83264, Sigma).
Solutions were microinjected using an 
InjectMan® NI 2 micromanipulator combined 
with a Femtojet microinjector (Eppendorf, 
Germany). The micromanipulator was 
mounted on an Axiovert 200 microscope 
(Zeiss, Germany). Pre-drawn capillaries with a 
tip diameter of 0.5 
 
m
 
m were used for 
microinjection (Femtotip®/Femtotip®II, 
Eppendorf). The Femtojet system allows the 
pressure of injection (150 kPa), time of 
injection (0.5 s) and background pressure 
(50 kPa, to counteract capillarity) to be set 
and thus control the amount injected. There 
are variations in how well the capillaries 
breach the cell membrane, and hence the 
amount of drug injected cannot be accurately 
quantified and can vary significantly among 
cells. Epirubicin (0.5 mg/mL) was co-injected 
with a 77 kDa fluorescein isothiocyanate 
(FITC)-dextran (0.5 mg/mL) into the cytoplasm 
of adherent cells. The FITC-dextran allowed 
the injected cell population to be clearly 
identified. FITC-dextrans of 77 kDa are 
ordinarily excluded from cells and cell nuclei, 
as they are too large to passively diffuse 
across these membranes. The injection buffer 
used was 48 mmol/L K
 
2
 
HPO
 
4
 
, 4.5 mmol/L 
KH
 
2
 
PO
 
4
 
, 14 mmol/L NaH
 
2
 
PO
 
4
 
, pH 7.2 
(Eppendorf, personal communication). All 
injection fluids were mixed in Eppendorf 
tubes and then centrifuged at 15 000 
 
g
 
 for 
3 min before transfer into capillaries, to 
ensure that any particles were separated from 
the injection liquid. Epirubicin precipitated 
 
FIG. 1. 
 
MGH-U1 cells 
 
(A) 
 
and MGH-U1R 
 
(B) 
 
incubated with epirubicin 
(10 
 
m
 
g/mL) for 60 min; the 
fluorescence images show a 
‘sensitive’ (A) nuclear uptake 
pattern of epirubicin and (B) 
characteristic nuclear sparing of 
epirubicin by MDR cells.
20 mm
A
20 mm
B
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slightly when mixed with injection buffer, but 
this precipitate was separated during 
centrifugation. Injection fluid was pipetted 
into capillaries using Eppendorf Microloaders, 
taking care not to stir up any precipitate. Once 
microinjected, cells were then incubated for 
60 min in normal culture conditions to allow 
cell recovery and time for the epirubicin to 
distribute within the cells. To show the normal 
sensitive and MDR patterns of epirubicin 
uptake for comparison, MGH-U1 and MGH-
U1R cells were incubated for 60 min with 
epirubicin 10 
 
m
 
g/mL in culture medium.
All cells were then viewed using a Zeiss LSM 
510 confocal microscope, through a 
 
¥
 
40 
water-immersion lens. Injected cells were 
easily identified on direct fluorescence 
microscopy by their green FITC-dextran 
fluorescence. Confocal microscopy allowed 
direct visualization of the distribution of the 
various fluophores within the microinjected 
cells. Epirubicin fluorescence was excited 
by a 543-nm HeNe laser and emission of 
wavelengths of 
 
≥
 
560 nm (red) detected. FITC-
dextran fluorescence was excited by a 488-
nm argon laser and emission wavelengths of 
505–530 nm (green) detected. The multitrack 
scanning mode on the confocal microscope 
was used to reduce cross interference in the 
fluorescence signals of these two fluophores.
Acridine orange (3 
 
m
 
g/mL) stains the nuclei of 
viable cells green and was added after initial 
image capture to confirm cell viability. 
Acridine orange has similar fluorescence 
properties to FITC and was detected with the 
same filter settings.
 
RESULTS
 
The epirubicin localization characteristics of 
MGH-U1 (sensitive) and MGH-U1R (MDR) cell 
lines after incubation with epirubicin 10 
 
m
 
g/
mL are shown in Fig. 1A,B. MGH-U1 cells 
showed a clear nuclear uptake pattern of 
epirubicin (Fig. 1A), whereas MGH-U1R cells 
showed characteristic nuclear sparing of 
epirubicin (Fig. 2B).
After microinjection with epirubicin the 
sensitive cell lines MGH-U1 and RT112 
showed clear nuclear uptake of epirubicin 
(Fig. 2A,B) consistent with their incubated 
uptake characteristics. However, the MDR cell 
lines, MGH-U1R and MGH-U1-MMC showed 
characteristic nuclear sparing of epirubicin 
 
FIG. 2. 
 
MGH-U1 cells 
 
(A) 
 
and RT112 cells 
 
(B) 
 
co-injected with epirubicin (0.5 mg/mL) and FITC-dextran 
(0.5 mg/mL). Bottom left: epirubicin fluorescence (red) showing a nuclear uptake pattern. Top left: FITC-
dextran fluorescence (green) excluded from the nucleus. Top right: differential interference contrast image. 
Bottom right: Integrated image.
20 mm 20 mm
20 mm 20 mmm
A
20 mm 20 mm
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after microinjection (Fig. 3A,B), again 
consistent with their incubated uptake 
characteristics.
The 77 kDa FITC-dextran allowed injected cells 
to be clearly identified, especially the resistant 
ones (otherwise showing low fluorescence) 
but was excluded from the nuclei of all 
injected cells, allowing clear visualization 
of nuclear epirubicin uptake, if present. 
Galleries of confocal slices through the 
depth of some cells were obtained (Fig. 4A,B). 
Reconstructing these to produce a three-
dimensional image of the cells visualized the 
epirubicin distribution three-dimensionally, 
allowing better localization of the exact 
cellular distribution of epirubicin and the 
FITC-dextran (Fig. 5A,B). Characteristically, 
the drug fluorescence associated with 
resistant cells was punctate, and on the 
surface or even outside the cells. The 
dextran fluorescence was evenly distributed 
through the cytoplasm. Acridine orange 
staining confirmed cell viability in all 
experiments.
 
DISCUSSION
 
Much has been reported about the nuclear-
sparing phenomenon shown by MDR cells 
when incubated with various anthracyclines 
[15–18] but there are few reports assessing 
the role of the nuclear membrane in this 
effect [22]. The present study is the first to 
assess the role of the nuclear membrane in 
MDR in viable, adherent bladder cancer cells 
 
in situ
 
.
Microinjection of drugs has clear advantages 
over standard exposure regimens for studying 
intracellular distribution in MDR cells. 
Previous investigators have questioned 
whether the nuclear-sparing phenomenon is 
merely a reflection of low levels of drug 
accumulation in MDR cells, because of drug 
efflux by P-gp, or whether the nuclear 
membrane is also active [22]. Microinjection 
of epirubicin bypasses the plasma membrane 
P-gp efflux pump, delivering a bolus of drug 
directly into the cytoplasm. There is still 
some efflux of the drug, as shown by the 
differences in overall drug fluorescence 
between sensitive and resistant cells, 
suggesting that the plasma membrane P-gp 
pump effluxes drug from the cell cytoplasm, 
and excludes drug while it crosses the plasma 
membrane, as suggested in previous studies 
[23,24].
 
FIG. 3. 
 
MGH-U1R cell 
 
(A) 
 
and MGH-U1-MMC cell 
 
(B) 
 
co-injected with epirubicin (0.5 mg/mL) and FITC-
dextran (0.5 mg/mL). Bottom left: epirubicin fluorescence (red) showing a nuclear-sparing pattern with 
cytoplasmic vesicular staining. Top left: FITC-dextran fluorescence (green) excluded from the nucleus. Top 
right: differential interference contrast image. Bottom right: integrated image.
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There was some delay in visualizing injected 
cells because of the location of the 
microinjection and confocal facilities at our 
institution, thus allowing time for some efflux 
to occur in the MDR cell samples. This delay 
also allowed time for the drug to be packaged 
in vesicles within the cytoplasm of MDR cells, 
as noted in previous confocal studies using 
standard anthracycline exposure methods 
[17].
The ability to reconstruct a three-dimensional 
image from serial stacks of confocal slices 
greatly enhances the visualization of 
epirubicin within injected cells, and allows 
clearer identification of nuclear uptake or 
sparing. The reconstructions strongly suggest 
that while almost all of the injected drug is 
sequestered into the nuclei of sensitive cells, 
resistant cell cytoplasm not only packages 
drug into vesicles, but takes it to the cell 
surface and expels it. There seemed to be very 
little drug in the cytosol.
The present results showed that cells 
microinjected with epirubicin had the same 
basic pattern of nuclear drug uptake or 
exclusion as cells incubated with epirubicin in 
the external milieu. They show that the 
nuclear membrane acts as a barrier to nuclear 
epirubicin uptake in MDR cells and must play 
a role in MDR. However, the mechanism(s) by 
which the nuclear membrane excludes 
epirubicin from the nuclei of MDR cells 
requires further investigation.
Possibilities include the expression of P-gp on 
the nuclear membrane causing drug efflux 
from the nucleus. One published study 
identified P-gp on the nuclear membrane 
of the MDR breast cancer cell line MCF-7 
DX [25] but another reported that P-gp was 
absent from the nuclear membrane of a 
lymphoblastic tumour cell line that had the 
MDR phenotype [26]. Direct immunostaining 
of P-gp in the present MDR line using cold 
acetone/ethanol fixation and JSB-1 detected 
no clear localization to the nuclear envelope 
(C. Davies, personal communication). More 
intensive studies of the location of P-gp in the 
present MDR bladder cell lines are needed.
Another possible mechanism may involve the 
numerous nuclear pore complexes that allow 
‘molecular trafficking’ between the nucleus 
and the cytoplasm. Nuclear pore complexes 
are large 120 MDa supramolecular assemblies 
that straddle the double-membrane of the 
nuclear envelope [27] and share the presence 
of the lung resistance protein with 
cytoplasmic vaults [28]. These nuclear pores 
allow passive diffusion of molecules up to 
40 kDa and the transport of larger molecules, 
up to several megadaltons, by energy-
dependent transport mechanisms, provided 
they carry a nuclear localization sequence 
that facilitates nuclear pore binding and 
transport [27].
Epirubicin is a small molecule of 
 
ª
 
0.5 kDa, so 
that by size criteria it should easily diffuse 
into nuclei via nuclear pores. However, the 
present results show that even when 
microinjected into MDR cells, epirubicin is 
excluded from the nucleus. This would seem 
to imply that either epirubicin is entering the 
nucleus and then being effluxed, or that it is 
denied entry into the nucleus in some way.
One possible explanation may be that 
epirubicin binds to proteins within the 
cytoplasm and is excluded from the nucleus if 
these proteins do not carry the nuclear 
localization sequence necessary for transport 
into the nucleus of MDR cells. This theory is 
 
FIG. 4. 
 
A gallery of confocal slices through a MGH-U1 cell 
 
(A) 
 
and a MGH-U1R cell 
 
(B) 
 
injected with epirubicin 
and FITC-dextran (integrated images).
A
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partly supported by previous work on the role 
of the nuclear membrane in adriamycin 
uptake in isolated sensitive and MDR nuclei, 
from a lymphoblastic tumour cell line [22]. 
This work showed that in isolated nuclei, 
nuclear transport of adriamycin (doxorubicin) 
is less in MDR cells than in sensitive cells. 
Furthermore, blockade of active nuclear 
transport by wheat germ agglutinin (
 
Triticum 
vulgaris
 
 lectin) reduced sensitive nuclear 
uptake of adriamycin to about the level of 
MDR nuclear uptake, but had no effect on 
adriamycin accumulation in MDR nuclei. This 
suggests that sensitive cells have two 
mechanisms by which nuclear adriamycin is 
taken up, i.e. passive diffusion and active 
transport. Adriamycin is thus transported into 
the nucleus of sensitive cells bound to 
proteins, whereas MDR cells allow adriamycin 
into their nuclei by passive diffusion only, 
with no active transport. This absence of 
active transport in MDR nuclei has several 
possible explanations, the two most probable 
being either that adriamycin binds to 
different proteins that do not carry the 
necessary sequence for nuclear transport, or 
that the nuclear localization sequence 
receptor on the nuclear pore complex is 
different in MDR cells. However, the isolated 
nuclei of sensitive and MDR cells in this study 
accumulated 10 times more drug than their 
whole-cell counterparts, suggesting that this 
system is not a good model of intracellular 
nuclear adriamycin handling. It is also 
questionable whether or not isolated nuclei 
remain ‘viable’, as nuclear drug uptake in 
nonviable MDR cells has been shown to be 
similar to nuclear uptake in viable sensitive 
cells [17]. This observation also clearly 
indicates the need to assess cell viability in 
any study evaluating drug uptake and 
localization in MDR cells, to ensure that 
nuclear staining is not the result of cell death. 
All cells in the present study were clearly 
viable on staining with acridine orange.
Further evidence to support the theory that 
sensitive cells transport anthracyclines into 
their nuclei bound to proteins, comes from a 
study showing, in sensitive leukaemic cells, 
that adriamycin was transported into nuclei 
bound to proteasomes [29]. Proteasomes are 
intracellular proteinase complexes involved in 
nonlysosomal protein degradation; they can 
be localized in both the cytoplasm and the 
nucleus, and hence carry the nuclear 
localization sequence necessary for active 
transport from the cytoplasm into the 
nucleus. The protein binding of anthracyclines 
in cells must be investigated further to assess 
if there are differences between sensitive and 
resistant cancer cells that may account for 
their differences in nuclear uptake.
Confocal microscopy allows semiquantitative 
measurements of nuclear fluorescence 
but because the quantity of epirubicin 
microinjected cannot be uniform among 
cells we were unable to compare nuclear 
fluorescence measurements among the 
different cell types in this study.
Like MDR, nuclear sparing has been shown 
in MDR cell lines from numerous organs, 
appearing to transcend tissue type. It is 
therefore likely that this mechanism is an 
important reason for chemotherapeutic 
failure in all tumours showing MDR. Nuclear 
sparing has also been reported using other 
fluorescent chemotherapeutic agents, e.g. the 
anthraquinones, which include mitoxantrone 
[18,30]. Difficulties in visualizing the 
cellular distribution of nonfluorescent 
chemotherapeutic agents makes it impossible 
to confirm that in MDR cells, nuclear sparing 
influences the efficacy of all MDR-affected 
anticancer agents and not just those that are 
autofluorescent.
In conclusion, the nuclear membrane, perhaps 
in association with proteasome-like carrier 
molecules, is important in mediating 
resistance by denying drugs access to their 
 
FIG. 5. 
 
A three-dimensional 
reconstruction of confocal slices 
through a MGH-U1 cell 
 
(A) 
 
and 
MGH-U1R cell 
 
(B) 
 
injected with 
epirubicin and FITC-dextran 
(fluorescence only).
A
B
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targets. If the mechanisms behind the role of 
the nuclear membrane in nuclear sparing and 
MDR can be elucidated further, they may 
provide further potential therapeutic targets 
for cancer treatment.
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